T CELLS AND PTH INDUCED BONE LOSS

T 细胞和 PTH 诱导的骨丢失

基本信息

  • 批准号:
    7646167
  • 负责人:
  • 金额:
    $ 32.24万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-08-24 至 2012-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Primary hyperparathyroidism (PHP) is a common cause of accelerated bone loss and osteoporosis. In spite of extensive investigation the mechanism of the bone catabolic action of PTH has not been not been completely elucidated. PHP is also an important cause of increased bone turnover, which is an independent risk factor for fractures. Studies in 4 in vivo and 5 in vitro models suggest that T cells provide survival, proliferative and pro-osteoclastogenic signals to bone marrow (BM) stromal cells (SCs) through the membrane-bound costimulatory molecule CD40L. As a result, T cell deficient mice are protected against PTH induced bone loss. This is due to the fact that BM SCs derived from T cell deficient mice are fewer in number, produce lower amounts of osteoclastogenic cytokines, and lack the capacity to support PTH induced osteoclast (OC) formation. The capacity of T cells to upregulate both the number and the osteoclastogenic activity of SCs is abolished by silencing of the PTH receptor PPR in T cells. We thus hypothesize that PTH directly stimulates T cells to promote SC osteoclastogenic activity by signaling through the PTH receptor PPR, and that T cells regulate SC number and activity through CD40L. The goal of this application is to determine the mechanism by which T cells mediate the bone catabolic activity of PTH. In Specific Aim 1 we will determine the phenotype of the T lymphocytes which are regulated by PTH, and mediate PTH induced bone loss. This will be accomplished by evaluating the effect of continuous PTH treatment in mice lacking specific T cell subsets. In Aim 2 we will determine the role of direct PPR signaling in T cells in PTH induced OC formation and bone loss. This will be accomplished by utilizing T cells from conditional KO mice which lack the PTH receptor in T cells. We will also determine if PPR signaling in T cells stimulate OC formation by generating T cell signals which upregulate the osteoclastogenic activity of SCs, and if PPR signaling in T cells increases their production of RANKL, TNF and IL-1, and their expression of CD40L. In Aim 3 we will determine if the capacity to regulate SC osteoclastogenic activity in a spontaneous fashion (as opposed to in response to PTH stimulation) and if in vivo silencing of CD40L prevent the increase in SC osteoclastogenic activity, OC formation and bone loss induced by PTH. The discovery of new mechanisms of action of PTH is relevant to public health as it may lead to the identification of novel therapeutic targets for PHP, osteoporosis and the bone disease associated with end stage renal disease. Our studies may also provide insights on strategies for augmenting the anabolic activity of intermittent PTH treatment. One such strategy could be that of antagonizing T cell production of osteoclastogenic factors.
描述(由申请人提供):原发性甲状旁腺功能亢进(PHP)是加速骨质流失和骨质疏松症的常见原因。尽管有广泛的研究,甲状旁腺激素骨分解代谢作用的机制尚未完全阐明。PHP也是骨转换增加的重要原因,这是骨折的独立危险因素。4个体内和5个体外模型的研究表明,T细胞通过膜结合的共刺激分子CD40L向骨髓(BM)基质细胞(SCs)提供存活、增殖和促破骨细胞生成信号。因此,T细胞缺陷小鼠可以防止甲状旁腺激素引起的骨质流失。这是由于来自T细胞缺陷小鼠的骨髓干细胞数量较少,产生的破骨细胞因子量较低,并且缺乏支持PTH诱导的破骨细胞(OC)形成的能力。T细胞通过沉默PTH受体PPR来消除T细胞上调SCs数量和破骨活性的能力。因此,我们假设PTH通过PTH受体PPR直接刺激T细胞促进SC破骨活性,T细胞通过CD40L调节SC数量和活性。本应用的目的是确定T细胞介导甲状旁腺激素骨分解代谢活性的机制。在特异性目标1中,我们将确定受甲状旁腺激素调节的T淋巴细胞的表型,并介导甲状旁腺激素诱导的骨质流失。这将通过评估在缺乏特异性T细胞亚群的小鼠中持续PTH治疗的效果来完成。在Aim 2中,我们将确定T细胞中直接PPR信号在PTH诱导的OC形成和骨质流失中的作用。这将通过利用T细胞中缺乏PTH受体的条件性KO小鼠的T细胞来完成。我们还将确定T细胞中的PPR信号是否通过产生上调SCs破骨活性的T细胞信号来刺激OC的形成,以及T细胞中的PPR信号是否增加RANKL、TNF和IL-1的产生以及CD40L的表达。在Aim 3中,我们将确定自发调节SC破骨活性的能力(而不是对PTH刺激的反应),以及体内CD40L的沉默是否能阻止PTH诱导的SC破骨活性的增加、OC形成和骨质流失。甲状旁腺激素的新作用机制的发现与公共卫生相关,因为它可能导致PHP,骨质疏松症和终末期肾脏疾病相关的骨病的新治疗靶点的确定。我们的研究也可能为增强间歇性甲状旁腺激素治疗的合成代谢活性的策略提供见解。其中一种策略可能是拮抗T细胞产生破骨细胞因子。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ROBERTO PACIFICI其他文献

ROBERTO PACIFICI的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ROBERTO PACIFICI', 18)}}的其他基金

Regulation of hemopoietic stem cell expansion by calciotrophic hormones
钙营养激素对造血干细胞扩增的调节
  • 批准号:
    8519417
  • 财政年份:
    2011
  • 资助金额:
    $ 32.24万
  • 项目类别:
Regulation of hemopoietic stem cell expansion by calciotrophic hormones
钙营养激素对造血干细胞扩增的调节
  • 批准号:
    8703679
  • 财政年份:
    2011
  • 资助金额:
    $ 32.24万
  • 项目类别:
Regulation of hemopoietic stem cell expansion by calciotrophic hormones
钙营养激素对造血干细胞扩增的调节
  • 批准号:
    8097069
  • 财政年份:
    2011
  • 资助金额:
    $ 32.24万
  • 项目类别:
Regulation of hemopoietic stem cell expansion by calciotrophic hormones
钙营养激素对造血干细胞扩增的调节
  • 批准号:
    8307233
  • 财政年份:
    2011
  • 资助金额:
    $ 32.24万
  • 项目类别:
In Vivo MicroCT Scanner
体内 MicroCT 扫描仪
  • 批准号:
    7797486
  • 财政年份:
    2010
  • 资助金额:
    $ 32.24万
  • 项目类别:
Ovariectomy Induced T Cell Inflammatory Cytokines/Bone Loss in Young & Old Mice
卵巢切除术诱导年轻人 T 细胞炎症细胞因子/骨质流失
  • 批准号:
    7849241
  • 财政年份:
    2009
  • 资助金额:
    $ 32.24万
  • 项目类别:
T CELLS AND PTH INDUCED BONE LOSS
T 细胞和 PTH 诱导的骨丢失
  • 批准号:
    7883442
  • 财政年份:
    2007
  • 资助金额:
    $ 32.24万
  • 项目类别:
T CELLS AND PTH INDUCED BONE LOSS
T 细胞和 PTH 诱导的骨丢失
  • 批准号:
    8098913
  • 财政年份:
    2007
  • 资助金额:
    $ 32.24万
  • 项目类别:
T Cells and PTH Induced Bone Loss
T 细胞和 PTH 诱导的骨丢失
  • 批准号:
    8544972
  • 财政年份:
    2007
  • 资助金额:
    $ 32.24万
  • 项目类别:
T Cells and PTH Induced Bone Loss
T 细胞和 PTH 诱导的骨丢失
  • 批准号:
    8373360
  • 财政年份:
    2007
  • 资助金额:
    $ 32.24万
  • 项目类别:

相似海外基金

Development of the preventive methods for sports-specific bone diseases in female athletes.
开发女运动员运动特异性骨疾病的预防方法。
  • 批准号:
    23K10643
  • 财政年份:
    2023
  • 资助金额:
    $ 32.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Defining the role of aggrecan and type IX collagen in osteoarthritis and osteochondritis dissecans through in vivo studies of genetic bone diseases
通过遗传性骨病的体内研究确定聚集蛋白聚糖和 IX 型胶原蛋白在骨关节炎和剥脱性骨软骨炎中的作用
  • 批准号:
    MR/X001873/1
  • 财政年份:
    2023
  • 资助金额:
    $ 32.24万
  • 项目类别:
    Research Grant
SIK Activators to Treat PTH Pathway Bone Diseases
SIK 激活剂治疗 PTH 通路骨疾病
  • 批准号:
    10811083
  • 财政年份:
    2023
  • 资助金额:
    $ 32.24万
  • 项目类别:
Functional analysis of a novel membrane transport factor in metabolic bone diseases
一种新型膜转运因子在代谢性骨疾病中的功能分析
  • 批准号:
    23K09507
  • 财政年份:
    2023
  • 资助金额:
    $ 32.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
17th Fellows Forum on Osteoporosis and Other Metabolic Bone Diseases
第十七届骨质疏松症和其他代谢性骨疾病研究员论坛
  • 批准号:
    10753107
  • 财政年份:
    2023
  • 资助金额:
    $ 32.24万
  • 项目类别:
Regenerative therapeutics of bone diseases by means of in situ direct reprogramming
通过原位直接重编程进行骨疾病的再生治疗
  • 批准号:
    21K19577
  • 财政年份:
    2021
  • 资助金额:
    $ 32.24万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Analysis of dysfunction of osteocytes to reveal the targets of treatment in genetical bone diseases
分析骨细胞功能障碍揭示遗传性骨病治疗靶点
  • 批准号:
    21H02881
  • 财政年份:
    2021
  • 资助金额:
    $ 32.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
15th Fellows Forum on Osteoporosis and Metabolic Bone Diseases
第十五届骨质疏松症和代谢性骨病研究员论坛
  • 批准号:
    10318312
  • 财政年份:
    2021
  • 资助金额:
    $ 32.24万
  • 项目类别:
Research for the development of methods to control age-related diseases and bone diseases
研究开发控制与年龄有关的疾病和骨疾病的方法
  • 批准号:
    20K20496
  • 财政年份:
    2020
  • 资助金额:
    $ 32.24万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Pioneering)
Exploration of druggable targets for metabolic bone diseases using sensitive reporter systems and integrative proteogenomic approaches
使用敏感报告系统和综合蛋白质组学方法探索代谢性骨疾病的药物靶点
  • 批准号:
    19KK0234
  • 财政年份:
    2019
  • 资助金额:
    $ 32.24万
  • 项目类别:
    Fund for the Promotion of Joint International Research (Fostering Joint International Research (B))
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了